Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 28, Issue 7, 2001, Pages 721-724

  Wassmann, B ^a   Klein, S A ^a   Scheuring, U ^a   Pfeifer, H ^a   Martin, H ^a   Gschaidmeier, H ^b   Hoelzer, D ^a   Ottmann, O G ^a  

^a GOETHE UNIVERSITY   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allogeneic stem cell transplantation; BCR ABL; Chronic myeloid leukemia; Cytogenetic remission; Donor chimerism; Tyrosine kinase

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; BUSULFAN; CD3 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN KINASE INHIBITOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CASE REPORT; CHIMERA; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; COLITIS; DIARRHEA; DONOR; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOCYTE TRANSFUSION; NAUSEA; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; COLITIS; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; IMMUNOSUPPRESSION; INTERFERON-ALPHA; LEUKEMIA, MYELOID, AGGRESSIVE-PHASE; LEUKEMIA, MYELOID, CHRONIC-PHASE; LYMPHOCYTE TRANSFUSION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEUTROPENIA; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034751358     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703222     Document Type: Article

References (16)

1. Chronic myeloid leukemia
2. Adoptive immunotherapy with donor lymphocyte transfusions
3. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
4. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand
5. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation
6. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse
7. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
8. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia
9. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
11. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation
12. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase
13. Allogeneic bone marrow transplantation for chronic myeloid leukemia
14. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges
15. A phase II study to determine the safety and antileukemic effects of ST1571 in adult patients with Philadelphia chromosome positive acute leukemias
16. Activity of an abl specific tyrosine kinase inhibitor in patients with ber-abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis